US law firm Parker Waichman has filed two lawsuits against Johnson & Johnson (J&J) and Janssen Pharmaceuticals related to their diabetes treatment drugs Invokana, Invokamet and Invokamet XR.

Filed in New Jersey State Court on behalf of two amputees, the complaint claimed that the sodium-glucose co-transporter-2 (SGLT2) inhibitor drugs enhance the risk of toes, feet and leg amputations.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

As per the complaint, both patients began using Invokana in early 2015 and had to undergo below the knee amputations in December.

Approved in the US in March 2013 and in the European Union (EU) in November 2013 for the treatment of type 2 diabetes, Invokana is reported to have had $1.31bn and $1.41bn sales in 2015 and 2016, respectively.

“As per the complaint, both patients began using Invokana in early 2015 and had to undergo below the knee amputations in December.”

In February last year, the European Medicines Agency (EMA) informed regarding potential increased risk of lower limb amputation in type 2 diabetes patients using canagliflozin (Invokana), dapagliflozin (Farxiga) and empagliflozin (Jardiance).

The Food and Drug Administration (FDA) confirmed the increased risk with canagliflozin (Invokana, Invokamet, Invokamet XR) in May last year by issuing a Drug Safety Communication based on new findings from two clinical trials.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The issued communication is reported to have required warnings to be added to the canagliflozin drug labels, describing the risk.

Parker’s lawsuits allege that J&J and Janssen have concealed and continue to conceal their knowledge that use of Invokana has unreasonably dangerous risks of lower limb amputations.

It was further added that the defective nature of the drug led to additional severe and permanent personal injuries such as kidney failure, diabetic ketoacidosis, stroke and heart attack.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact